ceritinib
Pfizer's Lorbrena Produces Longest Progression-Free Survival Seen in ALK-Positive NSCLC Patients
At five years, 60 percent of patients receiving first-line Lorbrena were alive without progression, according to Phase III data reported at ASCO.
Roche ALK Test Gains FDA Approval as CDx for Zykadia
The IHC test was used in clinical studies that led to Zykadia's approval last week as a first-line option for metastatic NSCLC patients with ALK rearrangements.
Novartis' Zykadia Approved for Frontline Treatment of Metastatic, ALK-Positive NSCLC
The expanded indication makes it a first-line option for metastatic non-small cell lung cancer patients with ALK rearrangements.